David Volkin

  • Ronald T. Borchardt Distinguished Professor
  • School of Pharmacy - Pharmaceutical Chemistry
Multidisciplinary Research Building Room (MRB), Room 304
University of Kansas
2030 Becker Drive
Lawrence, KS 66047


  • Ph.D., Biochemical Engineering, Massachusetts Institute of Technology
  • B.A., Chemistry, University of California, San Diego, (Revelle College)

Research Overview

David Volkin joined the KU faculty in 2010, after a 20-year career in the vaccine and biopharmaceutical industry, including senior director positions at Merck Research Laboratories (Merck) and Centocor R&D (J&J). He led groups responsible for analytical and formulation development of vaccines and therapeutic protein drugs. He has contributed to bringing dozens of candidates into human clinical trials, including five vaccines and three monoclonal antibody drugs now approved for commercial use. He is co-author of ~135 scientific publications and co-inventor on 15 U.S. patents, including the stabilization and formulation of the commercial human papillomavirus (Gardasil®) and rotavirus (RotaTeq®) vaccines. He was awarded the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Award in Biotechnology in 2015.

2nd among all schools of pharmacy in National Institutes of Health funding
Brings more than $20 million in external funding into the state each year
7 of 19 cancer drugs formulated through the National Cancer Institute were developed at the KU School of Pharmacy
3,000 free flu shots given to Kansans in need during the past 5 years
4,000 living alumni, 63 percent of them living and working in Kansas
KU pharmacists practice in 95 of Kansas’ 105 counties
20th among public schools of pharmacy.
—U.S. News & World Report
$20.2 million NIH research grant earned by Distinguished Professor Jeff Aubé was 2nd largest in Kansas history
100 percent placement after graduation for KU Pharm.D. students
Established in 1885 as the 1st professional program at KU